The South Africa biotechnology market driven by Growing demand for bio-based medicines, government support for research and development (R&D), rising healthcare needs, and increased investment in genetic engineering are driving market adoption. South Africa biotechnology market size reached USD 5.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 11.6 Billion by 2034, exhibiting a growth rate (CAGR) of 7.83% during 2026-2034. Agricultural biotechnology for food security, local manufacturing incentives, skilled workforce development, and international collaborations are also strengthening the industry and its visibility across the African continent.
How AI is Reshaping the Future of South Africa Biotechnology Market?
- AI-driven drug discovery and protein modeling are shortening early-stage research timelines for vaccines, biosimilars, and diagnostics, helping local firms address regional health burdens such as HIV, tuberculosis, and malaria more efficiently.
- Machine learning applied to genomic and DNA sequencing datasets is accelerating the development of drought-tolerant and pest-resistant crop varieties suited to South Africa’s semi-arid soils and climate, supporting national food security goals.
- AI-enabled process control in fermentation, cell-based assays, and biomanufacturing is improving yield consistency and quality assurance, which supports the push toward local vaccine and biologics production.
- Bioinformatics platforms powered by AI help research institutions and universities manage large clinical and genomic datasets, enabling precision medicine, oncology research, and cell and gene therapy programs.
- Public-private partnerships are increasingly adding AI analytics to R&D collaborations, helping funders prioritize high-impact projects and track outcomes across the biotechnology ecosystem.
Grab a sample PDF of this report: https://www.imarcgroup.com/south-africa-biotechnology-market/requestsample
Market Growth Factors
The South Africa biotechnology market is driven by rapid growth in agricultural biotechnology, as the country needs sustainable food production and resilience against climate change. Farmers are adopting genetically modified (GM) crops such as maize and cotton to raise yields and reduce dependence on pesticides. Drought-tolerant varieties have gained strong traction in semi-arid regions. Government biosafety regulations permit GM crop cultivation under strict oversight, which gives growers and seed developers a clear compliance pathway. Research institutes and universities are working with global biotech companies to develop crops suited to local conditions, while smallholder farmers are gradually embracing biotech solutions as productivity gains become visible. This positions South Africa as a leader in agricultural biotechnology across the continent.
Rising investment in healthcare biotechnology is a second major driver. Funding is flowing into vaccine development, diagnostics, and biologic therapies, with a strong focus on building local production capability rather than relying on imports. Biovac, for example, is developing what is described as Africa’s first end-to-end multi-vaccine manufacturing facility with a reported investment of R1.5 billion, backed by the European Investment Bank, the European Commission, and the International Finance Corporation. The Afrigen-led mRNA technology transfer hub in Cape Town, supported by the World Health Organization, adds to this base. Together, these initiatives are building manufacturing hubs for vaccines, biosimilars, and advanced diagnostics tailored to regional health challenges.
Government policy and industrialization support further strengthen the market. The Department of Science, Technology and Innovation (DSTI) funds R&D, skills development, and infrastructure under the national Science, Technology and Innovation Decadal Plan, with attention to pandemic preparedness and vaccine manufacturing. Investment incentives and international collaboration are encouraging biotech manufacturing hubs, and a high-end biomanufacturing training hub at the Council for Scientific and Industrial Research (CSIR) is addressing skills shortages. Startups are also diversifying into cell and gene therapy, precision medicine, and oncology, supported by the country’s strong research universities and scientific talent pool.
Market Segmentation
Product Type Insights:
- Instruments
- Reagents
- Software and Services
Technology Insights:
- Nanobiotechnology
- Tissue Engineering and Regeneration
- DNA Sequencing
- Cell-Based Assays
- Fermentation
- PCR Technology
- Chromatography
- Others
Application Insights:
- Healthcare
- Food and Agriculture
- Natural Resources and Environment
- Industrial Processing
- Bioinformatics
- Others
Regional Insights:
- Gauteng
- KwaZulu-Natal
- Western Cape
- Mpumalanga
- Eastern Cape
- Others
Recent Development & News
- May 2026: South Africa launched Biovac’s expanded vaccine manufacturing facility in Cape Town. The expansion strengthens local vaccine production and pandemic preparedness for the continent, and it builds on DSTI’s long-running support for the company and for the WHO-backed mRNA technology transfer hub.
- April 2026: The European Investment Bank Group, the European Commission, and the International Finance Corporation announced support for Biovac’s development of Africa’s first end-to-end multi-vaccine manufacturing facility. The project contributes to the Team Europe initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+).
- May 2025: South Africa’s Department of Science, Technology and Innovation (DSTI), together with GIZ and with support from the EU and BMZ, awarded grants to six biotechnology projects under the SAVax programme. The initiative strengthens vaccine development and production capacity by funding partnerships between research institutions and the private sector.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
